- Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs
- Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia
- The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms
- Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests
Bioscience pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), pursuing its goal of developing psychedelic drug treatments for diseases that otherwise have unmet medical needs, is continuing to prepare for an upcoming Phase 2a clinical trial for treating eating disorders by forging partnerships with professionals experienced in conducting such trials.
The company’s recent announcement that it will collaborate with psychedelic therapy educational platform Fluence in a master service agreement to provide design and training for the…
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.